Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
McKinsey
QuintilesIMS
Teva
Boehringer Ingelheim
Medtronic
Accenture
Cipla
Harvard Business School

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 012329

« Back to Dashboard

NDA 012329 describes ISMELIN, which is a drug marketed by Novartis and is included in one NDA. Additional details are available on the ISMELIN profile page.

The generic ingredient in ISMELIN is guanethidine monosulfate. There are two drug master file entries for this compound. Additional details are available on the guanethidine monosulfate profile page.
Summary for 012329
Tradename:ISMELIN
Applicant:Novartis
Ingredient:guanethidine monosulfate
Patents:0
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 012329

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrengthEQ 10MG SULFATE
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrengthEQ 25MG SULFATE
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Fuji
US Department of Justice
Covington
Merck
Healthtrust
Express Scripts
QuintilesIMS
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.